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A B S T R A C T
Purpose: To validate the Danish version of the Neurological Disorders Depression Inventory for Epilepsy
(NDDI-E), and compare it with the World Health Organization index for psychological well-being (WHO-
5) as screening tests for depression and anxiety in epilepsy patients.
Methods: Epilepsy outpatients ﬁlled out NDDI-E and WHO-5. A Mini International Neuropsychiatric
Interview (MINI) as gold standard for psychiatric diagnoses was carried out with every patient.
Results: We included 124 epilepsy patients. According to MINI, 5% had depression without anxiety, 6%
anxiety without depression, and 6% had both. For the detection of depression, NDDI-E was slightly better
than WHO-5. With a score of more than 13, NDDI-E as a screening tool for depression had a sensitivity of
0.92, a speciﬁcity of 0.84, a positive predictive value (PPV) of 0.40, and a negative predictive value (NPV)
of 0.99. In the detection of anxiety WHO-5 was better than NDDI-E. With a score below 50, WHO-5 as
screening for anxiety had a sensitivity of 0.80, a speciﬁcity of 0.92, PPV 0.57, and NPV 0.97. When
combining NDDI-E > 13 and WHO-5 < 50, 95% of patients with depression and/or anxiety are identiﬁed,
and in addition there are 17% false positives.
Conclusion: NDDI-E in Danish is valid and slightly better than WHO-5 in the detection of depression in
epilepsy patients. WHO-5 is valid for the detection of anxiety disorders. Combined use of NDDI-E and
WHO-5 is recommended, since 95% of all epilepsy patients with depression and/or anxiety disorder are
identiﬁed with only a modest number of false positives.
 2015 The Authors. ISDN. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
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In the treatment of epilepsy patients the relatively frequent
occurrence of depression and anxiety often go unnoticed and
therefore untreated [1–3]. In order to discover depression in
epilepsy patients, the Neurological Disorder Depression Inven-
tory for Epilepsy (NDDI-E) has been developed [4]. NDDI-E has
been translated from English to other languages and validated as
a screening tool for depression in epilepsy patients [5–15].
Recently, we published a Danish translation of NDDI-E [16]. The
ﬁrst purpose of the present study was to validate the Danish
NDDI-E.
WHO-5 is a questionnaire with ﬁve positive statements, which
measure mental well-being in the past two weeks [17]. WHO-5 has* Corresponding author. Tel.: +45 23 10 55 83.
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nd/4.0/).a value between 0 and 100. In a population study WHO-5 was in
average 70, whereas depressive patients had a mean score of about
30 [17]. The second purpose of the present study was to examine
WHO-5 as a screening test for depression and compare it with
NDDI-E in epilepsy patients.
Anxiety, like depression, is also a relatively frequent
companion of epilepsy [3], but detection of anxiety may be
more difﬁcult in epilepsy patients because no epilepsy speciﬁc
inventory for anxiety exists. Furthermore, there are several
different anxiety disorders including panic disorder, agorapho-
bia, social phobia, and generalized anxiety. The third purpose of
our study was to investigate whether WHO-5 or NDDI-E could be
used in the detection of anxiety disorders in patients with
epilepsy.
The fourth and ﬁnal purpose of the study was to investigate if a
combination of NDDI-E and WHO-5 would be better than either
test alone in the identiﬁcation of both depression and anxiety
disorders in epilepsy patients.rticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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2.1. Subjects
Adult patients with epilepsy treated at the epilepsy outpatient
clinic, Department of Neurology, University Hospital of North
Zealand, Hillerød, were included from October 1st 2013 to April
30th 2015. The inclusion criteria were as follows: age 18 years or
above, diagnosis of epilepsy according to criteria by the
International League Against Epilepsy, MRI or CT scan of the
brain, EEG, treatment with at least one antiepileptic drug in a
constant dose in the previous month, and the ability to read and
speak Danish. Exclusion criteria were severe medical or psychiatric
comorbidity and inability to read and/or speak Danish.
2.2. Flow of patients
All patients received oral and written information. After
informed consent to participate in the study, patients were given
the following self-report inventories:
 Neurological Disorder Depression Inventory for Epilepsy (NDDI-
E)
 World Health Organization Well-being Index (WHO-5)
 Major Depression Inventory (MDI)
 Anxiety Symptom Scale (ASS)
2.3. The Mini International Neuropsychiatric Interview version 5.0.0
(MINI)
The patients included in the study returned to the outpatient
clinic for a focused neuropsychiatric interview. A Danish version of
the Mini International Neuropsychiatric Interview version 5.0.0
(MINI) was used. MINI is a validated interviewer-administered,
structured, diagnostic psychiatric interview for DSM-IV [18]. We
used MINI as the gold standard for current psychiatric diagnosis.
MINI was carried out before examining the self-report inventories
which the patients ﬁlled out at home and brought to the interview.
Patients, who were diagnosed with a psychiatric disorder, were
offered treatment according to local practice.
2.4. The Neurological Disorder Depression Inventory for Epilepsy
(NDDI-E)
This screening tool for depression was developed for use
speciﬁcally in patients with epilepsy [4]. It consists of six statements
about the past two weeks that are scored between 1 (never) and 4
(always/often), with a minimum score of 6 and maximum of 24. In
the original version, a score above 15 has been shown to have high
predictive value for major depression [4]. Recently, we have
published a translation of NDDI-E to Danish [16].
2.5. The World Health Organization Well-being Index (WHO-5)
The WHO-5 consists of ﬁve items. Each item is rated on a 6-
point scale from 0 to 5. The score ranges from 0 to 25. The
percentage value is calculated by multiplying the score by 4 and
thus obtaining a scale from 0 (worst) to 100 (best). A percentage
score below 50 is interpreted as indicating risk of depression and
anxiety [17,19].
2.6. The Major Depression Inventory (MDI)
This scale contains the items that cover the ICD-10 symptoms of
depression. We used the MDI as a diagnostic tool requiring coresymptoms of depression to be present most of the time for the past
two weeks [17].
2.7. The Anxiety Symptom Scale (ASS)
The ASS consists of 10 items. The presence of the items on levels
0–5 in the previous 14 days is assessed. The ASS was considered
positive when item 10, the impact on daily activities, had a score of
three or more, and there was a score on the top three symptoms
which are the actual anxiety symptoms [17].
2.8. Statistics
We used SAS 9.3. Continuous data were compared using
unpaired t-tests. The Chi-square test was used for categorical data
and Fisher’s exact test if the cells had a frequency of ﬁve or less.
P < 0.05 was considered statistically signiﬁcant. Excel was used to
calculate sensitivity, speciﬁcity, positive predictive value (PPV),
negative predictive value (NPV), receiver operating characteristic
(ROC) curves and area under the curve (AUC).
2.9. Ethics
The study was approved by the Ethical Committee of the Capital
Region of Denmark (H-3-2012-086, anm. no. 39222). All patients
gave their written informed consent prior to inclusion in the study.
3. Results
3.1. Basic characteristics
A total of 124 patients were included in this study. Of these
21 patients (17%) were diagnosed with depression (n = 6), anxiety
(n = 8) or both in combination (n = 7). The group of patients with an
anxiety disorder included 3 patients with generalized anxiety and
12 patients with one or two of the disorders panic disorder,
agoraphobia, and social phobia. Other MINI-veriﬁed diagnosis
found were dysthymia (n = 5), alcoholism (n = 9), dissocial
personality disorder (n = 1), obsessive compulsive disorder
(n = 1) and current mania (n = 1). In Table 1 the basic data are
shown.
3.2. Screening for depression
Fig. 1 shows ROC curves for NDDI-E (A) and WHO-5 (B) as
screening tests for depression in epilepsy patients. The ROC curves
are based on 124 epilepsy patients including 13 patients (10.5%)
with depression. The AUC for the two curves are almost identical
(AUCNDDI-E = 0.932, AUCWHO-5 = 0.916). The ideal test has a
sensitivity of 1 and speciﬁcity of 1, which means that the point
on the ROC curve closest to the top left corner is the best possible
combination of sensitivity and speciﬁcity. In the original English
version of NDDI-E [4], a threshold of 15 was found to be optimal. In
the present study 18 patients scored above 15.
However, the best combination of sensitivity, speciﬁcity, PPV
and NPV was found with a cut-off value of >13 for NDDI-E and <50
for WHO-5. 29 patients had a score below 50 in WHO-5. With a
cut-off value > 13, the NDDI-E outweighs the WHO-5 (<50) with
higher sensitivity and slightly higher PPV and NPV, see
Table 2. The NDDI-E cut-off value > 13 was also used in the
subsequent tables.
Table 2 also shows the sensitivity, speciﬁcity, PPV and NPV for
MDI. The sensitivity of MDI as a screening tool for depression in
epilepsy patients is low (0.308). Depression was indicated by MDI
in 7 patients, but only 4 of these were true positive.
Table 2
The best combination of sensitivity, speciﬁcity, PPV, and NPV for NDDI-E and WHO-
5 compared to MDI when screening for depression in 124 epilepsy patients.
According to MINI 13 patients (10.5%) had depression.
Screening for depression
Sensitivity Speciﬁcity PPV NPV
NDDI-E > 13 0.923 0.838 0.400 0.989
WHO-5 < 50 0.846 0.838 0.379 0.979
MDI 0.308 0.972 0.571 0.922
Table 1
Basic characteristics of patients with no MINI-veriﬁed psychiatric disorders,
patients with current depression and/or anxiety disorder, and patients with other
psychiatric disorders.











Subjects, n 98 (79%) 21 (17%) 5 (4%)
Age, mean years (SD) 52 (17.8) 44 (14.0)* 48 (11.8)
Female, n 47 (48%) 12 (57%)* 5 (100%)
WHO-5, mean (SD)
All 72.6 (17.6) 36.6 (20.2)* 48.8 (11.8)
Current depression – 24 (20.1)* –
Current anxiety – 46.5 (21.3)* –
Both – 36 (10.5)* –
NDDI-E, mean (SD)
All 8.8 (3) 15.8 (3.4)* 13.8 (3.1)
Current depression – 16.8 (1.8)* –
Current anxiety – 14 (3.1)* –
Both – 17 (3.8)* –
* Indicates statistically signiﬁcant difference between patients with psychiatric
comorbidity and epilepsy patients without psychiatric comorbidity.
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Fig. 2 shows the ROC curves for NDDI-E (A) and WHO-5 (B) as
screening tests for any anxiety disorder in epilepsy patients. The
ROC curves are based on 124 epilepsy patients including











Fig. 1. ROC curves for detection of depression in epilepsy patients. The curve is based on t
NDDI-E (AUCNDDI-E = 0.932) and B the curve for WHO-5 (AUCWHO-5 = 0.916).











Fig. 2. ROC curves for detection of anxiety in epilepsy patients. The curve is based on the st
(AUCNDDI-E = 0.867) and B the curve for WHO-5 (AUCWHO-5 = 0.862).AUC for NDDI-E and WHO-5 were almost identical (AUCNDDI-
E = 0.867, AUCWHO-5 = 0.862), but somewhat lower than the AUC
under the curves for depression in Fig. 1. The best combination of
sensitivity, speciﬁcity, PPV and NPV for NDDI-E was found with a
cut-off value of >12, and for WHO-5 < 50. With these cut-off
values, WHO-5 outweighs the NDDI-E with higher speciﬁcity and
PPV (see Table 3). ASS has a very low sensitivity (0.200) as a
screening test for anxiety in epilepsy patients. MDI indicated
anxiety in 8 patients.
3.4. Combined screening for depression and anxiety disorders
By screening the 124 epilepsy patients for the presence of
depression or any anxiety disorder or both by NDDI-
E > 13 combined with WHO-5 < 50, we identiﬁed 20 of the
21 patients with depression, anxiety or both. Therefore, Table 4
shows a sensitivity of 0.95. The speciﬁcity is somewhat lower, 0.79,
as there were 21 false positives of 103 patients without depression
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udy of 124 epilepsy patients where 15 (12.1%) had anxiety. A is the curve for NDDI-E
Table 3
The best combination of sensitivity, speciﬁcity, PPV and NPV for NDDI-E and WHO-
5 compared to ASS when screening for anxiety disorders in 124 epilepsy patients.
According to MINI 15 patients (12.1%) had anxiety.
Screening for anxiety disorders
Sensitivity Speciﬁcity PPV NPV
NDDI-E > 12 0.800 0.798 0.343 0.967
WHO-5 < 50 0.800 0.917 0.571 0.971
ASS 0.200 0.954 0.375 0.896
Table 4
Combined effect of screening 124 epilepsy patients for depression and anxiety
disorders using NDDI-E > 13 and WHO-5 < 50. According to MINI 21 patients
(16.9%) had depression or Anxiety or both.
Screening for depression and anxiety
disorders
Sensitivity Speciﬁcity PPV NPV
NDDI-E > 13 or WHO-5 < 50 0.95 0.79 0.49 0.99
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only 1 of 83 negative screens was false negative.
4. Discussion
The most important ﬁnding in the present study was that it was
possible to identify 95% of all epilepsy patients with depression or
anxiety or both by combining NDDI-E and WHO-5. To our
knowledge, this is the ﬁrst published validated combined
screening for depression and anxiety in epilepsy patients. We
believe that it is also the ﬁrst validation of WHO-5 as screening test
for depression and anxiety in epilepsy patients.
In the original publication of NDDI-E, a score above 15 was
found to be optimal for the identiﬁcation of depression in epilepsy
patients [4]. Subsequently, NDDI-E has been translated from
English into Portugese, Italian, Spanish, Japanese, German, Korean,
Greek, Arabic, French, Chinese, and Danish [5–16]. By the
validation, the optimal threshold for detection of depression in
epilepsy patients was NDDI-E above 15 in six, above 11 in one
(Korean), above 13 in two, above 14 in one, and above 16 in one of
the other studies. We have now validated the Danish version of
NDDI-E and found that a threshold of NDDI-E above 13 is optimal.
It is remarkable that six short and negative statements can be used
in a reliable and valid way to identify depression in epilepsy
patients in so many languages and cultures across the world. The
reason for the apparent global utility of NDDI-E must be the global
occurrence of depression in epilepsy patients [3] and the initial
development of NDDI-E, which excluded confounding factors,
mainly side effects of antiepileptic drugs and cognitive conse-
quences of epilepsy [4]. When interpreting the positive and
negative predictive values of NDDI-E and other tests it should be
kept in mind that PPV and NPV do not have universal validity but
depend on the prevalence of the disease. In the present study, the
prevalence of depression was 10.5%. Consequently, the values of
PPV and NPV in Table 2 are valid for a Danish epilepsy population
with a prevalence of depression of 10.5%.
WHO-5 is the ﬁve item World Health Organization Well-Being
Index, which was published ﬁrst in 1998 and reviewed very recently
[19]. WHO-5 is a sensitive and speciﬁc screening tool for depression,
and it is applicable across many study ﬁelds [19]. However, the
present study is to our knowledge the ﬁrst published study on WHO-
5 as a screening tool for depression in epilepsy patients. Generally,
WHO-5 which may vary from 0 to 100, indicates risk of depression
with a score below 50, and patients with depression and without
epilepsy were found to have an average WHO-5 score of around 32,whereas persons who are not diagnosed with a mental disorder have
average WHO-5 around 66 [17]. In the present study epilepsy
patients with depression had an average WHO-5 score of 24, and the
group of epilepsy patients without a psychiatric diagnosis had an
average WHO-5 of 72.6. Thus, the WHO-5 values for epilepsy
patients with and without depression match the respective values
for persons without epilepsy.
Furthermore, our results show that WHO-5 with a cut off score
below 50 is almost as good as NDDI-E with a cut off score above
13 in the detection of depression in epilepsy patients. This is
remarkable, since NDDI-E consists of six negative statements
which directly indicate depression, whereas WHO-5 consists of
ﬁve positive statements indicating psychological well-being.
Although many factors could potentially reduce the psychological
well-being of an individual as measured by WHO-5, depressions
reduce WHO-5 more than any other factor [17].
Depression and anxiety often coexist in patients with epilepsy–
and also in persons without epilepsy [3]. The question is how to
identify patients with an anxiety disorder without depression.
Using MINI we identiﬁed 15 epilepsy patients with anxiety. The
majority had panic attack disorder, agoraphobia, social phobia or a
combination of two of these anxiety disorders, and a few patients
had generalized anxiety disorder. Recently, the inventory GAD-7
assessing generalized anxiety disorder has been found useful in
epilepsy patients with this anxiety disorder [20]. However, to our
knowledge the remaining types of anxiety have not been identiﬁed
with speciﬁc inventories in epilepsy patients. Furthermore,
epilepsy patients who are not seizure free typically fear new
seizures and their consequences. The inﬂuence of this understand-
able fear on the outcome of screening tests for anxiety remains to
be studied scientiﬁcally.
In the present study, looking at the 15 patients with different
anxiety disorders NDDI-E with a threshold above 12 yielded values
for sensitivity, speciﬁcity, and PPV lower than NDDI-E > 13 values
for depression. Thus, NDDI-E is better in identifying depression
than anxiety.
WHO-5 was better than NDDI-E in detecting anxiety in epilepsy
patients. In anxiety patients without epilepsy WHO-5 has been
found to be in average around 45 [17]. The epilepsy patients with
anxiety in the present study had an almost identical average WHO-
5 (46.5). Setting the screening score of WHO-5 to values below
50 will therefore enable the identiﬁcation of patients with anxiety
disorder.
The most important result of our study is that a combination of
NDDI-E with at cut off score above 13 and WHO-5 below 50 will
correctly identify 95% of the epilepsy patients who suffer from
depression, anxiety, or both. A NPV of 0.99 means a risk of only 1%
of depression or anxiety in patients with a negative screening
result of the two tests. Since both NDDI-E and WHO-5 are short and
simple, they could be ﬁlled out by the patient in the waiting room
and assessed quickly by the physician at the epilepsy control in the
outpatient clinic. If the screening indicates depression or anxiety, a
MINI or some other diagnostic interview should be carried out to
set the diagnosis. Our results show that the combined use of WHO-
5 and NDDI-E led to identiﬁcation of 21 patients (out of 124) who
did not fulﬁll the criteria for depression or anxiety disorder. These
17% were false positives. We ﬁnd this acceptable, because the
diagnostic procedure is harmless to the patient, the extra time
spent on MINI is modest, and most of all because the 20 of the
21 epilepsy patients suffering from depression and/or anxiety will
be identiﬁed systematically, so they can be offered treatment.
Furthermore, we suspect that the false positives are in increased
risk of depression and anxiety and should be followed more
closely. Future controlled studies of treatment of depression and
anxiety in epilepsy patients could use the approach for patient
identiﬁcation presented above.
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patients for identiﬁcation of depression and anxiety, respectively.
The explanation is most likely, that only few epilepsy patients have
severe depression and anxiety. We found in our previous study
using Hamilton’s depression and anxiety scales that the diagnosed
depressions and anxiety disorders in epilepsy patients were light
or moderate [16].
In conclusion, the present study shows that the Danish NDDI-E
with a cut off score above 13 is a valid tool for identiﬁcation of
depression in epilepsy patients. WHO-5 with a cut off score below
50 is almost equally good. With a WHO-5 cut off score below 50 it
is possible to identify the majority of epilepsy patients with
anxiety. Consequently, we recommend the combined use of NDDI-
E and WHO-5 for clinical screening of epilepsy patients for
depression and anxiety.
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